Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Phase I Treatment Active 18 and over NCI DFCI-03110 NCI-6051, NCT00072436, 6051

Objectives

Primary

1. Determine the maximum tolerated dose of gemcitabine and flavopiridol in patients with solid tumors.

Secondary

1. Determine the safety profile and toxic effects of this regimen in these patients.
2. Determine the pharmacokinetics of flavopiridol with and without gemcitabine in these patients.
3. Determine, using pharmacodynamic assays, the activity of flavopiridol as a cdk inhibitor in these patients.
4. Determine, using pharmacodynamic assays, the markers of this regimen in these patients.

Entry Criteria

Disease Characteristics:

• Histologically confirmed solid tumor for which gemcitabine is a treatment option OR for which no efficacious therapy exists



• Must meet criteria for 1 of the following:
  • Measurable disease
    • At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
  • Nonmeasurable disease, including any of the following:
    • Small lesions (less than 20 mm by conventional techniques OR less than 10 mm by spiral CT scan)
    • Bone lesions
    • Cytologically positive pleural or peritoneal disease
    • Elevated tumor markers (e.g., carcinoembryonic antigen, CA 125, CA 19-9, or other tumor marker)
    • Multinodular or confluent nonmeasurable pulmonary, hepatic, adrenal, intra-abdominal, or skin metastases



• No active CNS metastases
  • Previously treated CNS metastases must be stable with no symptoms for 4 weeks after completion of treatment AND patient must be off steroid therapy or on a stable dose for at least the past 2 weeks



• No known leptomeningeal metastases

Prior/Concurrent Therapy:

Biologic therapy

• Not specified

Chemotherapy

• No more than 2 prior chemotherapy regimens
  • Prior combined modality therapy (e.g., full-dose chemotherapy with radiosensitizing chemotherapy and radiotherapy) is considered 1 prior regimen if all therapy was delivered as part of 1 comprehensive treatment plan
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• No other concurrent chemotherapy

Endocrine therapy

• See Disease Characteristics

Radiotherapy

• See Chemotherapy
• At least 6 months since prior radiotherapy to the lung parenchyma or mediastinum and no evidence of radiation pneumonitis on chest CT scan
• At least 4 weeks since other prior radiotherapy and recovered
• No prior radiotherapy to more than 50% of marrow volume
• No concurrent radiotherapy

Surgery

• Not specified

Patient Characteristics:

Age

• 18 and over

Performance status

• ECOG 0-1

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count at least 1,500/mm³
• Platelet count at least 100,000/mm³

Hepatic

• See Disease Characteristics
• Bilirubin no greater than 1.5 mg/dL
• SGOT no greater than 2.5 times upper limit of normal

Renal

• See Disease Characteristics
• Creatinine no greater than 1.5 mg/dL

  OR

• Creatinine clearance at least 50 mL/min

Cardiovascular

• None of the following within the past 6 months:
  • Myocardial infarction
  • Unstable angina
  • Transient ischemic attack
  • Cerebrovascular accident
• No new cardiac arrhythmia possibly related to cardiac ischemia
• No large and potentially symptomatic pericardial effusion
• No cardiac disease that would preclude study participation

Pulmonary

• See Disease Characteristics
• No pulmonary embolism within the past 6 months
• No large and potentially symptomatic pleural effusion
• No pulmonary disease that would preclude study participation

Gastrointestinal

• No intractable emesis
• No grade 2 or greater chronic diarrheal disease within the past 6 months

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active infection
• No severe malnutrition

Expected Enrollment

A total of 40-80 patients will be accrued for this study.

Outcomes

Maximum tolerated dose as measured by safety and observed data collected every 28 days

Antitumor activity as measured by CT, MRI, or positron emission test (PET) scans at every other course

Outline

This is a dose-escalation, multicenter study.

Some patients receive an initial dose of flavopiridol IV over 1-7 hours on day 1 (course 0). Beginning 1 week later and for all subsequent courses, all patients receive gemcitabine IV over 60-150 minutes on days 1 and 15 and flavopiridol IV over 1-7 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of gemcitabine and flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment at that dose.

Patients are followed at 30 days after study completion.

Trial Contact Information

Trial Lead Organizations

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Geoffrey Shapiro, MD, PhD, Protocol chair		Ph: 617-632-4942; 866-790-4500 Email: geoffrey_shapiro@dfci.harvard.edu

U.S.A.
Massachusetts
	Boston
	Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
		Geoffrey Shapiro, MD, PhD	Ph:  617-632-4942 866-790-4500
			Email: geoffrey_shapiro@dfci.harvard.edu
	Massachusetts General Hospital
		Clinical Trials Office - Massachusetts General Hospital	Ph:  877-726-5130
New York
	New York
	Memorial Sloan-Kettering Cancer Center
		Gary K. Schwartz, MD	Ph:  212-639-8324 800-525-2225

Registry Information
Official Title		A Phase I Trial Of Gemcitabine Followed By A Short Infusion Of Flavopiridol In Patients With Solid Tumors
Trial Start Date		2003-09-30
Trial Completion Date		2005-11-08 (estimated)
Registered in ClinicalTrials.gov		NCT00072436
Date Submitted to PDQ		2003-10-01
Information Last Verified		2007-10-07
NCI Grant/Contract Number		CA06516, CA62490

Back to Top